MODERNITY IN THE TREATMENT OF ERECTILE DYSFUNCTION: LEVITRA (VARDENAFIL) IN THE FORM OF ORAL DISPERSIBLE TABLET


Cite item

Full Text

Open Access Open Access
Restricted Access Access granted
Restricted Access Subscription or Fee Access

Abstract

Due to high efficiency, prompt action and low incidence of side effects, phosphodiesterase type 5 inhibitors are the drugs of first choice in the treatment of erectile dysfunction (ED). One of the most widely used drugs in this group currently is vardenafil. Vardenafil has a number of properties that distinguish it from other drugs in this group: high selectivity and the highest inhibitory activity. Recently, new form of this drug, an oral-dispersible tablet (Levitra ODT) was developed. It dissolves in the mouth for a few seconds and does not required to drink water. This feature Levitra ODT enables easy administration of the drug, which provides the desired effect at any time and in any circumstances. Studies have shown that of simplicity of drug intake is one of the most important characteristics of the "ideal" treatment for erectile dysfunction from the point of view of patients. Currently, Levitra ODT is available at a dose of 10 mg. Two large, randomized, double-blind placebo-controlled studies, POTENT I and POTENT II, with participation of more than 700 patients with erectile dysfunction divided into 2 age groups, have shown a high efficacy and good tolerability of Levitra ODT in both groups. Thus, Levitra ODT is a new and promising form of the drug vardenafil, more convenient to use. There is no doubt that Levitra ODT will occupy an important place in the arsenal of modern methods of treatment of erectile dysfunction due to its high efficacy, good tolerability and usability.

Full Text

Restricted Access

References

  1. Rosen R.C., Fisher W.A., Eardley I. et al. The multinational Men's Attitudes to Life Events and Sexuality (MALES) study: I. Prevalence of erectile dysfunction and related health concerns in the general population. Curr Med Res Opin 2004;20:607-617.
  2. Canguven O., Burnett A.L. The effect of 5 alpha-reductase inhibitors on erectile function. J Androl. 2008;29:514-523.
  3. Corbin J.D., Francis S.H. Pharmacology of phosphodiesterase-5 inhibitors. Int. J Clin. Pract. 2002;56:453-459.
  4. Francis S.H., Corbin J.D. Molecular mechanisms and pharmacokinetics of phosphodiesterase-5 antagonists. Curr. Urol. Rep. 2003;4:457-465.
  5. Blount M.A., Beasley A., Zoraghi R. et al. Binding of tritiated sildenafi l, tadalafi l, or vardenafi l to the phosphodiesterase-5 catalytic site displays potency, specifi city, heterogeneity, and cGMP stimulation. Mol. Pharmacol. 2004;66:1: 144-152.
  6. Gbekor E., Bethell S., Fawcett L. et al. Phosphodiesterase 5 inhibitor profiles against all human phosphodiesterase families: implications for use as pharmacological tools. J Urol. 2002;167:(Suppl. 246):967.
  7. Saenz de Tejada I., Angulo J., Cuevas P. et al. The phosphodiesterase inhibitory selectivity and the in vitro and in vivo potency of the new PDE5 inhibitor vardenafi l. Int. J Impot. Res. 2001;13:5:282-290.
  8. Doh H., Shin C.Y., Son M. et al. Mechanism of erectogenic effect of the selective phosphodiesterase type 5 inhibitor, DA-8159. Arch. Pharm. Res. 2002;25:6:873-878.
  9. Goldstein I., Young J.M., Fischer J. et al. Vardenafil, a new phosphodiesterase type 5 inhibitor, in the treatment of erectile dysfunction in men with diabetes: a multicenter double-blind placebo-controlled fixed-dose study. Diab. Care. 2003;26:777-783.
  10. Hellstrom W.J., Elhilali M., Homering M. et al. Vardenafil in patients with erectile dysfunction: achieving treatment optimization. J. Androl. 2005;26:604-609.
  11. Hellstrom W.J. Vardenafil: a new approach to the treatment of erectile dysfunction. Curr. Urol. Rep. 2003;4:479-487.
  12. Miner M., Gilderman L., Bailen J. et al. Vardenafil in men with stable statin therapy and dyslipidemia. J Sex. Med. 2008;5:1455-1467.
  13. Nehra A., Grantmyre J., Nadel A. et al. Vardenafil improved patient satisfaction with erectile hardness, orgasmic function and sexual experience in men with erectile dysfunction following nerve sparing radical prostatectomy. J Urol. 2005;173:2067-2071.
  14. Heinig R., Weimann B., Dietrich H. et al. Pharmacokinetics of a new orodispersible tablet formulation of vardenafil: results of three clinical trials. Clin. Drug Investig. 2011;31:27-41.
  15. Dowson A.J., Charlesworth B.R. Patients with migraine prefer zolmitriptan orally disintegrating tablet to sumatriptan conventional oral tablet. Int. J Clin. Pract. 2003;57:573-576.
  16. de Argila C.M., Ponce J., Marquez E. et al. Acceptability of lansoprazole orally disintegrating tablets in patients with gastro-oesophageal reflux disease : ACEPTO study. Clin. Drug Investig. 2007;27:765-770.
  17. Debrune F.M., Gittelman M., Sperling H. et al. Time to onset of action of vardenafil: a retrospective analysis of the pivotal trials for the orodispersible and film-coated tablet formulations. J Sex. Med. 2011;8(10):2912-2923.
  18. Sanford M. Vardenafil orodispersible tablet. Drugs. 2012;72:87-98.
  19. Sperling H., Debruyne F., Boermans A. et al. The POTENT I randomized trial: efficacy and safety of an orodispersible vardenafil formulation for the treatment of erectile dysfunction. J Sex. Med. 2010;7:1497-1507.
  20. Gittelman M., McMahon C.G., Rodriguez-Rivera J.A. et al. The POTENT II randomised trial: efficacy and safety of an orodispersible vardenafil formulation for the treatment of erectile dysfunction. Int. J Clin. Pract. 2010;64:594-603.
  21. Arnold W.P., Mittal C.K., Katsuki S. et al. Nitric oxide activates guanylate cyclase and increases guanosine 3':5'-cyclic monophosphate levels in various tissue preparations. Proc. Natl. Acad. Sci. USA. 1977;74:3203-3207.
  22. Sperling H., Gittelman M., Norenberg C. et al. Efficacy and safety of an orodispersible vardenafil formulation for the treatment of erectile dysfunction in elderly men and those with underlying conditions: an integrated analysis of two pivotal trials. J Sex. Med. 2011;8:261-271.
  23. Jackson G., Rosen R.C., Kloner R.A. et al. The second Princeton consensus on sexual dysfunction and cardiac risk: new guidelines for sexual medicine. J Sex. Med. 2006;3:28-36.

Supplementary files

Supplementary Files
Action
1. JATS XML
Download

This website uses cookies

You consent to our cookies if you continue to use our website.

About Cookies